Our scioDiscover service enables high-content, immuno-based analysis of various biological samples leading to a comprehensive overview of proteomic changes. Key pathways in various diseases such as cancer, neurological disorders and organ failure are covered. The technology was successfully applied in a variety of biomedical studies and to discover new biomarker…
Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised range of protein profiling services available. These help you to speed up your research and generate important data at lower…
scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway…
Personalised Medicine and Diagnostic Research require techniques to discover and verify novel and more accurate Biomarkers. We offer a comprehensive immuno-based Protein Biomarker Discovery Service using complex Antibody Microarrays. This…
Be sure that your antibody is fit for your application. Profile your therapeutic or diagnostic antibody against more than 9000 human proteins. Have a comprehensive cross-reactivity and off-target reactivity profile…
The Scio-Extract Protein Extraction Buffers are optimised for superior protein isolation performance from all cell compartments and of membrane proteins. Their non-denaturing properties enable the extraction of active proteins under…
Microarrays - tailor-made for you. With more than 10 years of experience, Sciomics is the ideal partner for designing and printing your antibody-, protein-, peptide- or DNA/RNA chips. Benefit from…
New article | Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines.
| July 2016 | One of our customer projects was published in Cancer Research. In this study Bakdash et al. analysed the expansion of a BDCA1+CD14+ myeloid cell population in the context of immune therapy of melanoma. Within this study a protein profiling of cellular patient samples was performed with scioCD antibody arrays.
Interview | Advanced Biomarkers for Precision Medicine
New article | Analysis of the blood protein profile in B-cell lymphoma patients
| 12.12.2013 | There is a new article in the current issue of Proteomics Clinical Applications on an analysis of the blood protein profile of different B-cell lymphoma using complex antibody microarrays. 200 blood samples from patients with Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL) as well as healthy controls were analysed and compared with each other. The study identified proteins with discriminating power among the different lymphoma types, as well as subgroups within each lymphoma entity.
New article | Prediction of recurrence in bladder cancer
| 08.05.2014 | In a study published in Proteomics we identified proteins with differential abundance in bladder tumours with and without a local recurrence using antibody array technology. Next to interesting differences of the two tumour subtypes from a scientific point of view, we found a protein biomarker signature with high potential for a prognosis. This could enabling urologists in future to adjust the therapy and surveillance scheme accordingly. Further validation studies are ongoing. →Case study report
RNA has a very short life time of only 2 minutes - look at proteins to avoid experimental bias - scioDiscover -… https://t.co/M6wFNYaDrE
2 days ago
Precision Medicine - from proteomic discovery to clinical application. Join our webinar on 30th October, 3:30pm CET: https://t.co/fWiJZdFyOC
9 days ago
Precision Medicine - from proteomic discovery to clinical application. Join our webinar on 30th October, 3:30pm CET: https://t.co/vzzSqhb1pD
31 days ago
"We absolutely recommend Sciomics to everyone interested in an antibody array service" -from Prof Gräler -Thank you! https://t.co/RJvdhMZxRa